Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis

References

• Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. Jama. 2020;323(8):709–710.
   PubMed Web of Science ®Google Scholar
• Murgadella-Sancho A, Coloma-Conde A, Oriol-Bermúdez I. Impact of the Strategies Implemented by an Antimicrobial Stewardship Program on the Antibiotic Consumption in the Covid-19 Pandemic. Infect Control Hosp Epidemiol. 2021;1–5. https://doi.org/10.1017/ice.2021.237
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• WHO COVID-19 Dashboard. Geneva: world Health Organization; 2020 [ cited 2021 23 May]. Available from: https://covid19.who.int
   Google Scholar
• Rawson TM, Ming D, Ahmad R, et al. Antimicrobial use, drug-resistant infections and COVID-19. Nature Rev Microbiol. 2020;18(8):409–410.
   PubMed Web of Science ®Google Scholar
• Hamidi AA, Yilmaz Ş. Antibiotic consumption in the hospital during COVID-19 pandemic, distribution of bacterial agents and antimicrobial resistance: a single-center study. J Surg Med. 2021;5(2):124–127
   Google Scholar
• Aldeyab M, López-Lozano J-M, Gould IM. Global antibiotics use and resistance. Global Pharmaceutical Policy: Springer; 2020. p. 331–344.
   Google Scholar
• O’Neill J. Review on Antimicrobial Resistance: tackling a crisis for the health and wealth of nations. UK; 2014.
   Google Scholar
• King LM, Lovegrove MC, Shehab N, et al. Trends in US outpatient antibiotic prescriptions during the COVID-19 pandemic. Clinl Infect Dis. 2020;70(3):370–377.
   PubMed Web of Science ®Google Scholar
• Malcolm W, Seaton RA, Haddock G, et al. Impact of the COVID-19 pandemic on community antibiotic prescribing in Scotland. JAC Antimicrob Resist. 2020;2(4):dlaa105.
   PubMedGoogle Scholar
• Sulis G, Batomen B, Kotwani A, et al. Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: an interrupted time series analysis. PLoS Med. 2021;18(7):e1003682.
   PubMed Web of Science ®Google Scholar
• Abelenda-Alonso G, Padullés A, Rombauts A, et al. Antibiotic prescription during the COVID-19 pandemic: a biphasic pattern. Infect Control Hosp Epidemiol. 2020 07; 41(11): 1371–1372.
   PubMed Web of Science ®Google Scholar
• Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–275.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Buehrle DJ, Nguyen MHPRO, et al. pandemic will result in increased antimicrobial resistance rates. JAC Antimicrob Resist. 2020;2(3):3.
   Google Scholar
• Collignon P, Beggs JJ, Walsh TR, et al. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. Lancet Planet Health. 2018;2(9):e398–e405.
   PubMedGoogle Scholar
• Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: a Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020;71(9):2459–2468.
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. In Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2021; 27(4) :520–531.
   Google Scholar
• Tejedor Prado P, Lázaro Cebas A, Sánchez Artola B, et al. editors. 4CPS-246 Coronavirus first wave effect on antibiotic consumption and antimicrobial resistance. London, UK: British Medical Journal Publishing Group; 2021.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Zhu NJ, McLeod M, McNulty CAM, et al. Trends in Antibiotic Prescribing in Out-of-Hours Primary Care in England from January 2016 to June 2020 to Understand Behaviours during the First Wave of COVID-19. Antibiotics (Basel). 2021 Jan 1;10:1.
   Web of Science ®Google Scholar
• Liu H, Gao J, Wang Y, et al. Epidemiological and clinical characteristics of 2019 novel coronavirus disease (COVID-19) in Jilin, China: a descriptive study. Medicine (Baltimore). 2020;99:47.
   Web of Science ®Google Scholar
• Wells G, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Clin Epidemiol. 2016;
   Google Scholar
• Bank W. Data: country Classification 2021. [updated Jul 2021]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
   Google Scholar
• Zhu N, Aylin P, Rawson T, et al. Investigating the impact of COVID-19 on primary care antibiotic prescribing in North West London across two epidemic waves. In Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2021;27(5) :762–768 .
   Google Scholar
• Rezel-Potts E, Esperance V, Gulliford MC. Antimicrobial stewardship in the UK during the COVID-19 pandemic: a population-based cohort study and interrupted time-series analysis. Brjgenpract. 2021;71(706):e331–e338.
   Google Scholar
• Zhu NJ, McLeod M, McNulty CAM, et al. Trends in Antibiotic Prescribing in Out-of-Hours Primary Care in England from January 2016 to June 2020 to Understand Behaviours during the First Wave of COVID-19. Antibiotics (Basel). 2021;10:1.
   Web of Science ®Google Scholar
• Buehrle DJ, Nguyen MH, Wagener MM, et al. editors. Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. Open forum infectious diseases Oxford University Press US; 2020.
   Google Scholar
• Tan SH, Ng TM, Tay HL, et al. A point prevalence survey to assess antibiotic prescribing in patients hospitalized with confirmed and suspected coronavirus disease 2019 (COVID-19). J Glob Antimicrob Resist. 2021;24:45–47.
   PubMed Web of Science ®Google Scholar
• Ng TM, Tan SH, Heng ST, et al. Effects of coronavirus disease 2019 (COVID-19) pandemic on antimicrobial prevalence and prescribing in a tertiary hospital in Singapore. Antimicrob Resist Infect Control. 2021;10(1):28.
   PubMed Web of Science ®Google Scholar
• Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, et al. Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic. Antibiotics (Basel). 2021;10:2.
   Web of Science ®Google Scholar
• Blix HS, Høye S. Use of antibiotics during the COVID-19 pandemic. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2021;141:4.
   Google Scholar
• Fabre V, Karaba S, Amoah J, et al. The role of procalcitonin in antibiotic decision-making in Covid-19 infection. Infect Control Hosp Epidemiol. 2021 Apr;19:1–24.
   Web of Science ®Google Scholar
• Mustafa ZU, Salman M, Aldeyab M, et al. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compreh Clin Med. 2021;1–5 doi:https://doi.org/10.1007/s42399-021-00966-5.
   Google Scholar
• Pettit NN, Nguyen CT, Lew AK, et al. Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission. BMC Infect Dis. 2021;21(1):1–7.
   PubMed Web of Science ®Google Scholar
• Calderón-Parra J, Muiño-Miguez A, Bendala-Estrada AD, et al. Inappropriate antibiotic use in the COVID-19 era: factors associated with inappropriate prescribing and secondary complications Analysis of the registry SEMI-COVID. PloS One. 2021;16(5):e0251340.
   PubMed Web of Science ®Google Scholar
• Williams EJ, Mair L, de Silva TI, et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. J Hosp Infect. 2021;110:103–107.
   PubMed Web of Science ®Google Scholar
• Castro-Lopes A, Correia S, Leal C, et al. Increase of antimicrobial consumption in a tertiary care hospital during the first phase of the COVID-19 pandemic. Antibiotics. 2021;10(7):778.
   Web of Science ®Google Scholar
• Sulis G, Sayood S, Gandra S. Antimicrobial resistance in low- and middle-income countries: current status and future directions. In Expert review of anti-infective therapy. 2021.
   Google Scholar
• Buehrle DJ, Decker BK, Wagener MM, et al. Antibiotic consumption and stewardship at a hospital outside of an early coronavirus disease 2019 epicenter. Antimicrob Agents Chemother. 2020;64(11):11.
   Web of Science ®Google Scholar
• Townsend L, Hughes G, Kerr C, et al. Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC Antimicrob Resist. 2020 09; 2(3): dlaa071–dlaa071.
   PubMedGoogle Scholar
• Ponce-Alonso M, Sáez de La Fuente J, Rincón-Carlavilla A, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2021;42(4) :406–410.
   PubMed Web of Science ®Google Scholar
• Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2021 Jan;42(1):84–88.
   PubMed Web of Science ®Google Scholar
• Karami Z, Knoop BT, Dofferhoff ASM, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond). 2021;53(2) 10:102–110.
   PubMed Web of Science ®Google Scholar
• Rothe K, Feihl S, Schneider J, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. 2020 11; 40(4): 859–869.
   PubMed Web of Science ®Google Scholar
• Liu C. Antibiotic stewardship challenges in an evolving health-care market in China. Lancet Infect Dis. 2021;21(6):753–754.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Gibbons CL, Cooper L, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020 09; 81(6): 952–960.
   PubMed Web of Science ®Google Scholar
• Stevens RW, Jensen K, O’Horo JC, et al. Antimicrobial prescribing practices at a tertiary-care center in patients diagnosed with COVID-19 across the continuum of care. Infect Control Hosp Epidemiol. 2021;42(1):89–92.
   PubMed Web of Science ®Google Scholar
• Dieringer TD, Furukawa D, Graber CJ, et al. Inpatient antibiotic utilization in the Veterans’ Health Administration during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2021;42(6):751–753.
   PubMed Web of Science ®Google Scholar
• Staub MB, Beaulieu RM, Graves J, et al. Changes in antimicrobial utilization during the coronavirus disease 2019 (COVID-19) pandemic after implementation of a multispecialty clinical guidance team. Infect Control Hosp Epidemiol. 2021;42(7) :810–816.
   PubMed Web of Science ®Google Scholar
• Goncalves Mendes Neto A, Lo KB, Wattoo A, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med Virol. 2021 Mar;93(3):1489–1495.
   PubMed Web of Science ®Google Scholar
• Pedrotti CHS, Accorsi TAD, De Amicis Lima K, et al. Antibiotic stewardship in direct-to-consumer telemedicine consultations leads to high adherence to best practice guidelines and a low prescription rate. Int J Infect Dis. 2021;105:130–134.
   PubMed Web of Science ®Google Scholar
• Liu C, Wen Y, Wan W, et al. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Int Immunopharmacol. 2021 Jan 01;90:107157.
   PubMed Web of Science ®Google Scholar
• Molla MMA, Yeasmin M, Islam MK, et al. Antibiotic prescribing patterns at COVID-19 dedicated wards in Bangladesh: findings from a single center study. Infect Prav Pract. 2021 June 01;3(2):100134.
   PubMedGoogle Scholar
• Martinez-Guerra BA, Gonzalez-Lara MF, De-leon-cividanes NA, et al. Antimicrobial resistance patterns and antibiotic use during hospital conversion in the COVID-19 pandemic. 2021 03;10:2.
   Google Scholar
• Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. In The Lancet Microbe. 2021.
   Google Scholar
• Guisado-Gil AB, Infante-Domínguez C, Peñalva G, et al. Impact of the COVID-19 pandemic on antimicrobial consumption and hospital-acquired candidemia and multidrug-resistant bloodstream infections. Antibiotics (Basel). 2020;9:11.
   Web of Science ®Google Scholar
• Al-Azzam S, Mhaidat NM, Banat HA, et al. An assessment of the impact of coronavirus disease (COVID-19) pandemic on national antimicrobial consumption in jordan. Antibiotics. 2021;10(6):690.
   Web of Science ®Google Scholar
• Moretto F, Sixt T, Devilliers H, et al. Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19? Inter J Infect Dis. 2021;105:256–260.
   PubMed Web of Science ®Google Scholar
• Evans TJ, Davidson HC, Low JM, et al. Antibiotic usage and stewardship in patients with COVID-19: too much antibiotic in uncharted waters? J Infect Prev. 2021;22(3):119–125.
   PubMedGoogle Scholar
• Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clinl Infect Dis. 2021;72(10):e533–e541.
   PubMed Web of Science ®Google Scholar
• Staub MB, Beaulieu RM, Graves J, et al. Changes in antimicrobial utilization during the coronavirus disease 2019 (COVID-19) pandemic after implementation of amultispecialty clinical guidance team. Infect Control Hosp Epidemiol. 2021;42(7):810–816.
   PubMed Web of Science ®Google Scholar
• Mustafa L, Tolaj I, Baftiu N, et al. Use of antibiotics in COVID-19 ICU patients. J Infect Developing Countries. 2021;15(4):501–505.
   Google Scholar
• Monira P, Mahmuda Y M, Maruf Ahmed M. antimicrobial resistance, evidences on irrational anti-microbial prescribing and consumption during COVID-19 pandemic and possible mitigation strategies: a Bangladesh perspective. 2020.
   Google Scholar
• Easom N, Moss P, Barlow G, et al. Sixty‐eight consecutive patients assessed for COVID‐19 infection: experience from a UK regional infectious diseases unit. Influenza Other Respir Viruses. 2020;14(4):374–379.
   PubMed Web of Science ®Google Scholar
• Khamis F, Al-Zakwani I, Al Naamani H, et al. Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman. J Infect Public Health. 2020;13(7):906–913.
   PubMed Web of Science ®Google Scholar
• Gandra S, Barter D, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014;20(10):973–980.
   PubMed Web of Science ®Google Scholar
• Woolhouse M, Waugh C, Perry MR, et al. Global disease burden due to antibiotic resistance–state of the evidence. J Glob Health. 2016;6(1):1.
   Web of Science ®Google Scholar
• Li J, Song X, Yang T, et al. A systematic review of antibiotic prescription associated with upper respiratory tract infections in China. Medicine (Baltimore). 2016;95:19.
   Web of Science ®Google Scholar
• World Health Organization. Medicines use in primary care in developing and transitional countries: fact book summarizing results from studies reported between 1990 and 2006. Geneva: World Health Organization; 2009.
   Google Scholar
• Lucien MAB, Canarie MF, Kilgore PE, et al. Antibiotics and antimicrobial resistance in the COVID-19 era: perspective from resource-limited settings. Int J Infect Dis. 2021;104:250–254.
   PubMed Web of Science ®Google Scholar
• Jirjees FJ, Al-Obaidi HJ, Sartaj M, et al. Antibiotic Use and Resistance in Hospitals: Time-Series Analysis Strategy for Determining and Prioritising Interventions. Hosp. Pharm. Eur. 2020 :13–19. Available online: https://hospitalpharmacyeurope.com/news/reviews-research/antibiotic-use-and-resistance-in-hospitals-time-series-analysis-strategy-for-determining-and-prioritising-interventions/ [(accessed on 11 July 2021)]
   Google Scholar
• Monira PMMMA, Mahmuda YTNBAA, Ghosh AK. Evidences on irrational anti-microbial prescribing and consumption among COVID-19 positive patients and possible mitigation strategies: a descriptive cross sectional study. (Special Issue: pandemic COVID19). Bangladesh J Infect Dis. 2020;7(Supplementary Issue):S3–S7.
   Google Scholar
• Chedid M, Waked R, Haddad E, et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021 May;14(5):570–576.
   PubMed Web of Science ®Google Scholar
• Oldenburg CE, Doan T. Azithromycin for severe COVID-19. Lancet. 2020;396(10256):936–937.
   PubMed Web of Science ®Google Scholar
• Oliver ME, Hinks TSC. Azithromycin in viral infections. Rev Med Virol. 2020;2020:e2163–e2163.
   Google Scholar